RESUMEN
Taking leftover prescribed antibiotics without consulting a healthcare professional is problematic for the efficacy, safety, and antibiotic stewardship. We conducted a cross-sectional survey of adult patients in English and Spanish between January 2020 and June 2021 in six safety-net primary care clinics and two private emergency departments. We assessed the reasons for stopping prescribed antibiotics early and what was done with the leftover antibiotics. Additionally, we determined 1) prior leftover antibiotic use, 2) intention for future use of leftover antibiotics, and 3) sociodemographic factors. Of 564 survey respondents (median age of 51), 45% (251/564) reported a history of stopping antibiotics early, with 171/409 (42%) from safety net and 80/155 (52%) from the private clinics. The most common reason for stopping prescribed antibiotics early was "because you felt better" (194/251, 77%). Among survey participants, prior use of leftover antibiotics was reported by 149/564 (26%) and intention for future use of leftover antibiotics was reported by 284/564 (51%). In addition, higher education was associated with a higher likelihood of prior leftover use. Intention for future use of leftover antibiotics was more likely for those with transportation or language barriers to medical care and less likely for respondents with private insurance. Stopping prescribed antibiotics early was mostly ascribed to feeling better, and saving remaining antibiotics for future use was commonly reported. To curb nonprescription antibiotic use, all facets of the leftover antibiotic use continuum, from overprescribing to hoarding, need to be addressed.
Asunto(s)
Antibacterianos , Humanos , Antibacterianos/uso terapéutico , Masculino , Femenino , Persona de Mediana Edad , Estudios Transversales , Encuestas y Cuestionarios , Adulto , Programas de Optimización del Uso de los Antimicrobianos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Anciano , Servicio de Urgencia en Hospital/estadística & datos numéricos , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Atención Primaria de Salud/estadística & datos numéricosAsunto(s)
Antibacterianos , Depresión Posparto , Humanos , Pakistán/epidemiología , Femenino , Depresión Posparto/tratamiento farmacológico , Depresión Posparto/epidemiología , Antibacterianos/efectos adversos , Antibacterianos/administración & dosificación , Adulto , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Adulto Joven , EmbarazoRESUMEN
BACKGROUND: Chronic migraine exerts substantial negative impacts on daily functioning. Efforts to manage impaired functioning may result in medication overuse, which contributes to the worsening profile and chronification of migraine. The Migraine Functional Impact Questionnaire (MFIQ) is a recently developed measure assessing the impact of migraine on physical, social, and emotional function. OBJECTIVE: The objective of this analysis was to assess changes in MFIQ scores following initiation or modification of migraine preventive medication and determine if changes in function are associated with changes in other aspects of migraine burden, such as headache frequency, headache intensity, and symptoms of anxiety and depression. METHODS: This is a secondary analysis of data from the Medication Overuse Treatment Strategy (MOTS) trial, a prospective pragmatic clinical trial that investigated two treatment strategies for those with chronic migraine and medication overuse. Data from both treatment arms were pooled and analyzed using a pre-post design. Prior to and 12 weeks following initiation or modification of migraine preventive medication, participants completed a series of questionnaires that captured migraine characteristics, medication use, migraine-related physical impairment (MFIQ), anxiety (Generalized Anxiety Disorder-7), and depression (Patient Health Questionnaire 9 [PHQ-9]) symptoms. Changes from baseline in all measures were assessed using the paired t-test. Relationships between changes in MFIQ scores and other measures were assessed using linear regression. Multivariable modeling was performed to determine which additional variables contributed to the change in MFIQ beyond that already explained by an individual variable. Model terms were selected by using elastic net regularization. Only those participants who completed the baseline and 12-week MFIQ were included in this analysis. RESULTS: Of the 537 patients, 88.2% were female, and the average age was 45 years (standard deviation 13). The mean frequency of days with moderate-to-severe headache improved 39.2% from 13.5 per 30 days at baseline to 8.1 per 30 days at week 12. The mean MFIQ Usual Activities Global score improved by 15.0 points (on a 100-point scale). All five domains (Usual Activities Global, Usual Activities, Social Function, Emotional Function, Physical Function) of the MFIQ improved by a mean of at least 13.0 points. Changes in PHQ-9 score, followed by changes in headache frequency, had the strongest associations with change in all domains of the MFIQ. CONCLUSIONS: The negative impact of chronic migraine with medication overuse on physical, social, and emotional functioning substantially lessened following initiation or modification of migraine preventive medication. Improved functioning, as measured by the MFIQ, was most strongly associated with reductions in depression scores and headache frequency, highlighting the importance of recognizing and monitoring changes in depressive symptoms, in addition to headache frequency and functional impairment, when evaluating response to preventive medications.
Asunto(s)
Trastornos Migrañosos , Humanos , Trastornos Migrañosos/tratamiento farmacológico , Trastornos Migrañosos/prevención & control , Femenino , Masculino , Adulto , Persona de Mediana Edad , Enfermedad Crónica , Cefaleas Secundarias , Encuestas y Cuestionarios , Estudios Prospectivos , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Analgésicos/administración & dosificación , Depresión , Ansiedad/etiología , Resultado del TratamientoRESUMEN
OBJECTIVE: To investigate the misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury. STUDY DESIGN: Cross-sectional study. SETTING: Outpatient clinic in a physical therapy and rehabilitation hospital. PARTICIPANTS: 127 patients, aged 18-70 years, who had neuropathic pain related to spinal cord injury (SCI) and disease duration of at least 12 months. OUTCOME MEASURES: Gabapentinoid use disorder of the patients was determined based on the DSM-5 diagnostic criteria for substance-related disorders. Patients were divided into 2 groups as those with drug misuse and those without drug misuse. Demographic and clinical information of the patients were compared between the groups. Factors associated with drug misuse were analyzed. RESULTS: The misuse rate was 81.9% in patients using pregabalin and 69.69% in patients using gabapentin. Duration of disease and the Leeds assessment of neuropathic symptoms and signs (LANSS) score were statistically significantly higher in the drug misuse group. A statistically significant difference was found between the groups in terms of marital status, education and income level, and smoking and alcohol use. A statistically significant relationship was observed between drug misuse and duration of disease and LANSS score. CONCLUSION: Misuse of gabapentinoids is prevalent in patients with neuropathic pain related to spinal cord injury. The duration of disease and the severity of NP are associated with misuse. Clinicians should exercise caution when prescribing gabapentinoids to patients with SCI.
Asunto(s)
Analgésicos , Gabapentina , Neuralgia , Pregabalina , Uso Excesivo de Medicamentos Recetados , Traumatismos de la Médula Espinal , Adolescente , Adulto , Anciano , Humanos , Persona de Mediana Edad , Adulto Joven , Atención Ambulatoria , Analgésicos/uso terapéutico , Estudios Transversales , Gabapentina/uso terapéutico , Neuralgia/diagnóstico , Neuralgia/tratamiento farmacológico , Neuralgia/epidemiología , Neuralgia/etiología , Servicio Ambulatorio en Hospital/estadística & datos numéricos , Pregabalina/uso terapéutico , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Prevalencia , Factores de Riesgo , Traumatismos de la Médula Espinal/complicaciones , Traumatismos de la Médula Espinal/epidemiologíaRESUMEN
OBJECTIVE: Combination topical clotrimazole/ betamethasone dipropionate (C-BM) contains a high-potency topical corticosteroid and is not infrequently prescribed for inappropriate patient groups and body sites. Use of C-BM can lead to inadequate clearance or exacerbation of fungal infections as well as cutaneous atrophy, striae, and other skin maladies. METHODS: We performed a retrospective chart review of 1,978 clinical visits where C-BM was prescribed within the University of Utah Health system between 2014 and 2018 to better understand current prescribing patterns. RESULTS: 1,974 prescriptions were written for C-BM. 91.6% of patients were at least the recommended age of 17 years. C-BM was most commonly prescribed for rashes of an inflammatory (42.2%) or fungal nature (38.1%). Clotrimazole/betamethasone dipropionate was prescribed for sensitive areas (face, axillae, groin or diaper region) in 48.9% of patients. Family medicine clinicians prescribed 58.3% of C-BM prescriptions, whereas dermatology clinicians accounted for 3.4%. CONCLUSION: We strongly recommend clinicians use alternative treatments for rashes or refer to dermatologists.
Asunto(s)
Antifúngicos/uso terapéutico , Betametasona/análogos & derivados , Clotrimazol/uso terapéutico , Glucocorticoides/uso terapéutico , Micosis/tratamiento farmacológico , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Adolescente , Adulto , Betametasona/uso terapéutico , Niño , Combinación de Medicamentos , Femenino , Humanos , Modelos Logísticos , Masculino , Estudios RetrospectivosRESUMEN
BACKGROUND: Overuse of antibiotics is a major challenge and undermines measures to control drug resistance worldwide. Postnatal women and newborns are at risk of infections and are often prescribed prophylactic antibiotics although there is no evidence to support their universal use in either group. METHODS: We performed point prevalence surveys in three hospitals in Dar es Salaam, Tanzania, in 2018 to collect descriptive data on antibiotic use and infections, in maternity and neonatal wards. RESULTS: Prescribing of antibiotics was high in all three hospitals ranging from 90% (43/48) to 100% (34/34) in women after cesarean section, from 1.4% (1/73) to 63% (30/48) in women after vaginal delivery, and from 89% (76/85) to 100% (77/77) in neonates. The most common reason for prescribing antibiotics was medical prophylaxis in both maternity and neonatal wards. CONCLUSIONS: We observed substantial overuse of antibiotics in postnatal women and newborns. This calls for urgent antibiotic stewardship programs in Tanzanian hospitals to curb this inappropriate use and limit the spread of antimicrobial resistance.
Asunto(s)
Antibacterianos/administración & dosificación , Atención Posnatal/estadística & datos numéricos , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Salas de Parto , Femenino , Hospitales Públicos , Humanos , Recién Nacido , Enfermedades del Recién Nacido/prevención & control , Salas Cuna en Hospital , Embarazo , Complicaciones Infecciosas del Embarazo/prevención & control , Encuestas y Cuestionarios , TanzaníaRESUMEN
BACKGROUND AND OBJECTIVES: The American Academy of Pediatrics recommends against the routine use of ß-agonists, corticosteroids, antibiotics, chest radiographs, and viral testing in bronchiolitis, but use of these modalities continues. Our objective for this study was to determine the patient, provider, and health care system characteristics that are associated with receipt of low-value services. METHODS: Using the Virginia All-Payers Claims Database, we conducted a retrospective cross-sectional study of children aged 0 to 23 months with bronchiolitis (code J21, International Classification of Diseases, 10th Revision) in 2018. We recorded medications within 3 days and chest radiography or viral testing within 1 day of diagnosis. Using Poisson regression, we identified characteristics associated with each type of overuse. RESULTS: Fifty-six percent of children with bronchiolitis received ≥1 form of overuse, including 9% corticosteroids, 17% antibiotics, 20% ß-agonists, 26% respiratory syncytial virus testing, and 18% chest radiographs. Commercially insured children were more likely than publicly insured children to receive a low-value service (adjusted prevalence ratio [aPR] 1.21; 95% confidence interval [CI]: 1.15-1.30; P < .0001). Children in emergency settings were more likely to receive a low-value service (aPR 1.24; 95% CI: 1.15-1.33; P < .0001) compared with children in inpatient settings. Children seen in rural locations were more likely than children seen in cities to receive a low-value service (aPR 1.19; 95% CI: 1.11-1.29; P < .0001). CONCLUSIONS: Overuse in bronchiolitis remains common and occurs frequently in emergency and outpatient settings and rural locations. Quality improvement initiatives aimed at reducing overuse should include these clinical environments.
Asunto(s)
Bronquiolitis/tratamiento farmacológico , Uso Excesivo de los Servicios de Salud/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Radiografía Torácica/estadística & datos numéricos , Corticoesteroides/uso terapéutico , Agonistas Adrenérgicos beta/uso terapéutico , Antibacterianos/uso terapéutico , Bronquiolitis/diagnóstico por imagen , Estudios Transversales , Servicios Médicos de Urgencia , Femenino , Adhesión a Directriz , Humanos , Lactante , Recién Nacido , Seguro de Salud , Masculino , Distribución de Poisson , Estudios Retrospectivos , VirginiaRESUMEN
Benzodiazepines, often used to treat anxiety, insomnia, and other conditions, are prescribed more frequently to women than men, and emergency department visits and overdose deaths involving benzodiazepines have increased significantly among women in recent years. This study describes characteristics and trends associated with benzodiazepine exposures among women of reproductive age (15-49 years old) that were reported to United States poison control centers from 2004 through 2018. The National Poison Data System recorded 258,370 first-ranked benzodiazepine exposures among women 15-49 years old during the study period. More than one-half (56.9%) of exposures involved a single-substance and one-third (34.0%) occurred among women 20-29 years old. The majority were categorized as "intentional, suspected suicide" (73.2%) or "intentional" (12.9%). Exposures frequently resulted in admission to a psychiatric facility (20.6%), critical care unit (18.1%), or non-critical care unit (9.3%). Twenty percent of cases resulted in a serious medical outcome, including 205 deaths. The substantial percentage of benzodiazepine exposures among women of reproductive age that were intentional and associated with suicide attempts or suicide deaths indicate that increased prevention efforts are needed to address this issue.
Asunto(s)
Benzodiazepinas/toxicidad , Benzodiazepinas/uso terapéutico , Centros de Control de Intoxicaciones/estadística & datos numéricos , Centros de Control de Intoxicaciones/tendencias , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Uso Excesivo de Medicamentos Recetados/tendencias , Adolescente , Adulto , Femenino , Humanos , Persona de Mediana Edad , Estados Unidos/epidemiología , Adulto JovenRESUMEN
PURPOSE: To determine the rate and risk factors for new persistent opioid use after ophthalmic surgery in the United States. DESIGN: Retrospective claims-based cohort analysis. PARTICIPANTS: Opioid-naive patients 13 years of age and older who underwent incisional ophthalmic surgery between January 1, 2012, and June 30, 2017, and were included in Optum's de-identified Clinformatics Data Mart database. METHODS: New persistent opioid use was defined as filling an opioid prescription in the 90-day and the 91- to 180-day periods after the surgical procedure. The outcome variable was an initial perioperative opioid prescription fill. Rates of new persistent opioid use were calculated, and multivariate logistic regression models were used to identify variables increasing the risk of new persistent use and refill of an opioid prescription after the initial perioperative prescription in first 30 days. MAIN OUTCOME MEASURES: New persistent opioid use and refill. RESULTS: A total of 327 379 opioid-naive patients (mean age, 67 years [standard deviation, 16 years]; 178 067 women [54.4%]) who underwent ophthalmic surgery were examined. Among these patients, 14 841 (4.5%) had an initial perioperative opioid fill. The rate of new persistent opioid use was 3.4% (498 of 14 841 patients) compared with 0.6% (1833 of 312 538 patients) in patients who did not have an initial perioperative opioid fill. After adjusting for patient characteristics, initial perioperative opioid fill was associated independently with increased odds of new persistent use (adjusted odds ratio [OR], 6.21; 95% confidence interval [CI], 5.57-6.91; P < 0.001). Among patients who had filled an initial perioperative prescription, a prescription size of 150 morphine milligram equivalents or more was associated with an increased odds of refill (adjusted OR, 1.87; 95% CI, 1.58-2.22; P < 0.001). CONCLUSIONS: Exposure to opioids in the perioperative period is associated with new persistent use in patients who were previously opioid-naive. This suggests that exposure to opioids is an independent risk factor for persistent use in patients undergoing incisional ophthalmic surgery. Surgeons should be aware of those risks to identify at-risk patients given the current national opioid crisis and to minimize prescribing opioids when possible.
Asunto(s)
Analgésicos Opioides/uso terapéutico , Prescripciones de Medicamentos/estadística & datos numéricos , Procedimientos Quirúrgicos Oftalmológicos , Trastornos Relacionados con Opioides/epidemiología , Dolor Postoperatorio/tratamiento farmacológico , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Revisión de Utilización de Seguros , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Estados Unidos/epidemiologíaRESUMEN
Importance: Controlling antimicrobial resistance in health care is a public health priority, although data describing antimicrobial use in US nursing homes are limited. Objective: To measure the prevalence of antimicrobial use and describe antimicrobial classes and common indications among nursing home residents. Design, Setting, and Participants: Cross-sectional, 1-day point-prevalence surveys of antimicrobial use performed between April 2017 and October 2017, last survey date October 31, 2017, and including 15â¯276 residents present on the survey date in 161 randomly selected nursing homes from selected counties of 10 Emerging Infections Program (EIP) states. EIP staff reviewed nursing home records to collect data on characteristics of residents and antimicrobials administered at the time of the survey. Nursing home characteristics were obtained from nursing home staff and the Nursing Home Compare website. Exposures: Residence in one of the participating nursing homes at the time of the survey. Main Outcomes and Measures: Prevalence of antimicrobial use per 100 residents, defined as the number of residents receiving antimicrobial drugs at the time of the survey divided by the total number of surveyed residents. Multivariable logistic regression modeling of antimicrobial use and percentages of drugs within various classifications. Results: Among 15â¯276 nursing home residents included in the study (mean [SD] age, 77.6 [13.7] years; 9475 [62%] women), complete prevalence data were available for 96.8%. The overall antimicrobial use prevalence was 8.2 per 100 residents (95% CI, 7.8-8.8). Antimicrobial use was more prevalent in residents admitted to the nursing home within 30 days before the survey date (18.8 per 100 residents; 95% CI, 17.4-20.3), with central venous catheters (62.8 per 100 residents; 95% CI, 56.9-68.3) or with indwelling urinary catheters (19.1 per 100 residents; 95% CI, 16.4-22.0). Antimicrobials were most often used to treat active infections (77% [95% CI, 74.8%-79.2%]) and primarily for urinary tract infections (28.1% [95% CI, 15.5%-30.7%]). While 18.2% (95% CI, 16.1%-20.1%) were for medical prophylaxis, most often use was for the urinary tract (40.8% [95% CI, 34.8%-47.1%]). Fluoroquinolones were the most common antimicrobial class (12.9% [95% CI, 11.3%-14.8%]), and 33.1% (95% CI, 30.7%-35.6%) of antimicrobials used were broad-spectrum antibiotics. Conclusions and Relevance: In this cross-sectional survey of a cohort of US nursing homes in 2017, prevalence of antimicrobial use was 8.2 per 100 residents. This study provides information on the patterns of antimicrobial use among these nursing home residents.
Asunto(s)
Antiinfecciosos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos , Utilización de Medicamentos/estadística & datos numéricos , Casas de Salud/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Estudios Transversales , Femenino , Fluoroquinolonas/uso terapéutico , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Estados Unidos , Infecciones Urinarias/tratamiento farmacológicoRESUMEN
PURPOSE: Medication beliefs are likely contingent on aspects of health literacy: knowledge, motivation, and competences to access, understand, appraise, and apply health information. An association between medication beliefs and health literacy is expected as they both influence self-management. The aim of this study was to examine the association between health literacy and the beliefs about overuse and harmful effects of medication and to examine modifying effects of age, gender, and number of medications on this association. METHODS: The data were collected using the online "Medication panel" of the Dutch Institute for Rational Use of Medicine. A linear regression model was used to examine the association between health literacy and beliefs about medication and the modifying effects of age, gender, and number of medications on this association. RESULTS: Respondents with a lower level of health literacy had more concerns about overuse (ß adj.= -.174, p<.001) and harmful (ß adj.= -.189, p<.001) effects of medication. This study found no modifying effects. CONCLUSIONS: A lower health literacy level is associated with more concerns about the overuse and harmful effects of medication. The results of this study suggest that extra attention should be given to persons with low health literacy level by healthcare professionals, to decrease their concerns about overuse and harmful effects, and improve adherence to self-management behavior.
Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Alfabetización en Salud/estadística & datos numéricos , Cumplimiento de la Medicación/estadística & datos numéricos , Factores de Edad , Anciano , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Países Bajos , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Automanejo , Factores Sexuales , Factores SocioeconómicosAsunto(s)
Antibacterianos/administración & dosificación , Tratamiento Farmacológico de COVID-19 , COVID-19/epidemiología , Gripe Humana/tratamiento farmacológico , Gripe Humana/epidemiología , Pandemias , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/epidemiología , Adenoviridae/efectos de los fármacos , Adenoviridae/patogenicidad , Programas de Optimización del Uso de los Antimicrobianos , Azitromicina/administración & dosificación , COVID-19/virología , Cefalosporinas/administración & dosificación , Fluoroquinolonas/administración & dosificación , Humanos , Hidroxicloroquina/administración & dosificación , Incidencia , Virus de la Influenza A/efectos de los fármacos , Virus de la Influenza A/patogenicidad , Virus de la Influenza B/efectos de los fármacos , Virus de la Influenza B/patogenicidad , Gripe Humana/virología , Italia/epidemiología , Macrólidos/administración & dosificación , Penicilinas/administración & dosificación , Distanciamiento Físico , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Cuarentena/organización & administración , Virus Sincitiales Respiratorios/efectos de los fármacos , Virus Sincitiales Respiratorios/patogenicidad , Infecciones del Sistema Respiratorio/virología , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/patogenicidadRESUMEN
BACKGROUND: Knowledge on bacterial co-infections in COVID-19 is crucial to use antibiotics appropriately. Therefore, we aimed to determine the incidence of bacterial co-infections, antibiotic use and application of antimicrobial stewardship principles in hospitalized patients with COVID-19. METHODS: We performed a retrospective observational study in four hospitals (1 university, 2 non-university teaching, 1 non-teaching hospital) in the Netherlands from March to May 2020 including consecutive patients with PCR-confirmed COVID-19. Data on first microbiological investigations obtained at the discretion of the physician and antibiotic use in the first week of hospital admission were collected. RESULTS: Twelve (1.2%) of the 925 patients included had a documented bacterial co-infection (75.0% pneumonia) within the first week. Microbiological testing was performed in 749 (81%) patients: sputum cultures in 105 (11.4%), blood cultures in 711 (76.9%), pneumococcal urinary antigen testing in 202 (21.8%), and Legionella urinary antigen testing in 199 (21.5%) patients, with clear variation between hospitals. On presentation 556 (60.1%; range 33.3-73.4%) patients received antibiotics for a median duration of 2 days (IQR 1-4). Intravenous to oral switch was performed in 41 of 413 (9.9%) patients who received intravenous treatment >48 h. Mean adherence to the local guideline on empiric antibiotic therapy on day 1 was on average 60.3% (range 45.3%-74.7%). CONCLUSIONS: On presentation to the hospital bacterial co-infections are rare, while empiric antibiotic use is abundant. This implies that in patients with COVID-19 empiric antibiotic should be withheld. This has the potential to dramatically reduce the current overuse of antibiotics in the COVID-19 pandemic.
Asunto(s)
Antibacterianos/administración & dosificación , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/epidemiología , COVID-19/epidemiología , Pandemias , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Anciano , Programas de Optimización del Uso de los Antimicrobianos , Infecciones Bacterianas/microbiología , Cultivo de Sangre , COVID-19/virología , Coinfección , Vías de Administración de Medicamentos , Esquema de Medicación , Femenino , Adhesión a Directriz/estadística & datos numéricos , Hospitalización , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Países Bajos/epidemiología , Uso Excesivo de Medicamentos Recetados/prevención & control , Estudios Retrospectivos , SARS-CoV-2/patogenicidadAsunto(s)
Programas de Optimización del Uso de los Antimicrobianos , COVID-19/epidemiología , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/epidemiología , COVID-19/microbiología , COVID-19/virología , Estudios de Cohortes , Femenino , Humanos , Revisión de Utilización de Seguros , Masculino , Persona de Mediana Edad , República de Corea/epidemiología , Estudios Retrospectivos , Adulto JovenRESUMEN
INTRODUCTION: Fluoroquinolones (FQs) are a commonly prescribed class of antibiotics in Canada. Evidence of a constellation of possible adverse events is developing. Central and peripheral nervous system abnormalities and collagen-related events (including aortic aneurysm/dissection, tendinopathy/rupture and retinal detachment) are associated with FQ exposure in large population-based aftermarket studies. In 2017, Health Canada warned about rare FQ-related persistent or disabling side effects. This study explores FQ use in a rural community. METHODS: Antibiotic prescriptions (including FQs) in the over 18 adult population (5416) were measured in the town of Sioux Lookout for 5 years, January 2013 to 31 December 2017. RESULTS: FQ prescriptions accounted for 16.0% of adult antibiotics, superseded by penicillins (21.1%) and macrolides (18.2%). Ciprofloxacin accounted for one half of FQ use (51.2%), followed by levofloxacin (36.7%) and norfloxacin (13.3%). FQs were commonly used for respiratory (33%) and urinary tract infections (18%). CONCLUSION: Aftermarket evidence reports increased risk of 'disabling and persistent serious adverse events'(Health Canada) in patients using FQs. Appropriate clinical caution should be exercised in the prescribing of FQs. Common overuse seems to occur in the treatment of uncomplicated community-acquired pneumonia and cystitis, despite recommendations to use other antimicrobial agents as first-line treatments.
Résumé Introduction: Les fluoroquinolones sont une classe d'antibiotiques souvent prescrite au Canada. Mais les données étayant une gamme d'événements indésirables possibles s'accumulent. Des anomalies du système nerveux central et périphérique, et des événements liés au collagène (dont anévrisme ou dissection de l'aorte, tendinopathie/rupture et décollement de la rétine) sont associés à l'exposition aux fluoroquinolones dans des études de pharmacovigilance d'envergure basées sur la population. En 2017, Santé Canada a émis une mise en garde au sujet des effets indésirables rares, persistants ou incapacitants liés aux fluoroquinolones. Cette étude se penche sur l'emploi de fluoroquinolones dans une communauté rurale. Méthodologie: La prescription d'antibiotiques (y compris de fluoroquinolones) a été mesurée dans la ville de Sioux Lookout pendant 5 ans, soit de janvier 2013 au 31 décembre 2017 auprès de la population de 18 ans et plus (5416 personnes). Résultats: Les fluoroquinolones comptaient pour 16,0 % des antibiotiques prescrits aux adultes, elles étaient précédées des pénicillines (21,1 %) et des macrolides (18,2 %). La ciprofloxacine représentait la moitié de l'emploi de fluoroquinolones (51,2 %), suivie de la lévofloxacine (36,7 %) et de la norfloxacine (13,3 %). Les fluoroquinolones étaient fréquemment utilisées contre les infections respiratoires (33 %) et urinaires (18 %). Conclusion: Les données de pharmacovigilance rapportent un risque accru "d'événements indésirables graves persistants et incapacitants" (Santé Canada) chez les patients sous fluoroquinolones. La prudence clinique appropriée est de mise lors de la prescription de fluoroquinolones. La pneumonie extra-hospitalière non compliquée et la cystite semblent être à l'origine de la surutilisation, malgré les recommandations d'utiliser d'autres antimicrobiens en première intention. Mots-clés: Fluoroquinolones; antibiotiques; effets indésirables; rural.
Asunto(s)
Antibacterianos/efectos adversos , Fluoroquinolonas/efectos adversos , Prescripción Inadecuada/estadística & datos numéricos , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Población Rural/estadística & datos numéricos , Adulto , Sistemas de Registro de Reacción Adversa a Medicamentos , Antibacterianos/uso terapéutico , Fluoroquinolonas/uso terapéutico , Humanos , Prescripción Inadecuada/prevención & control , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina/estadística & datos numéricos , Uso Excesivo de Medicamentos Recetados/prevención & control , Adulto JovenRESUMEN
Forty per cent of French subjects over 65 years old with Alzheimer's disease and related disorders (MATA) are chronically exposed to antidepressants suggesting an overuse of these drugs. The main objective of our study was to estimate the prevalence and factors associated with overuse by antidepressants in this population. METHODOLOGY: Single-center, prospective, cross-sectional study carried out at the Bretonneau Day Hospital (HDJ) between December, 1st 2014 and May, 31 2015. Consecutive patients with ≥70 years of age, suffering from MATA (according to DSM IV criteria) and current prescription of antidepressant were eligible. Overuse was defined by off-label prescriptions or prescriptions beyond the recommended duration of treatment. It was assessed by the geritrician in charge and validated by an expert committee, blind from the geriatrician's assessment. RESULTS: Fifty-four patients were included in the study (mean age 82.9 years (+/- 5.4), 70.4% of women, 60% with mild to moderate dementia). The main indication of antidepressant treatment was a major depressive episode (59.3%). The geriatrician could not deal with overuse for 10 cases (18.5%). Inter-rater agreement between geriatricians and expert committee was good (kappa coefficient 0.73 [0.5-0.95]). Finally 33 (61%) of these patients had overuse of antidepressants: 1/3 had an off-label prescription and 2/3 had an exceeded treatment duration. The only factor associated with this overuse was coprescription of psychotropic drugs (p=0.009). CONCLUSIONS: Antidepressant overuse is common in demented older outpatients, especially overuse due to exceeded treatment duration. It is significantly associated with coprescription with another psychotropic drug, suggesting that it fits into a more global problem of overuse in psychotropic drugs.
Asunto(s)
Enfermedad de Alzheimer/complicaciones , Antidepresivos/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Trastorno Depresivo Mayor/etiología , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Atención Ambulatoria , Estudios Transversales , Femenino , Humanos , Masculino , Estudios ProspectivosRESUMEN
Importance: Children with severe neurological impairment (SNI) often take multiple medications to treat problematic symptoms. However, for children who cannot self-report symptoms, no system exists to assess multiple symptoms and their association with medication use. Objectives: To assess the prevalence of 28 distinct symptoms, test whether higher global symptom scores (GSS) were associated with use of more medications, and assess the associations between specific symptoms and medications. Design, Setting, and Participants: This cross-sectional study was conducted between April 1, 2019, and December 31, 2019, using structured parent-reported symptom data paired with clinical and pharmacy data, at a single-center, large, hospital-based special health care needs clinic. Participants included children aged 1 to 18 years with SNI and 5 or more prescribed medications. Data analysis was performed from April to June 2020. Exposure: During routine clinical visits, parent-reported symptoms were collected using the validated 28-symptom Memorial Symptom Assessment Scale (MSAS) and merged with clinical and pharmacy data. Main Outcomes and Measures: Symptom prevalence, counts, and GSS (scored 0-100, with 100 being the worst) were calculated, and the association of GSS with medications was examined. To evaluate associations between symptom-medication pairs, the proportion of patients with a symptom who used a medication class or specific medication was calculated. Results: Of 100 patients, 55.0% were boys, the median (interquartile range [IQR]) age was 9 (5-12) years, 62.0% had 3 or more complex chronic conditions, 76.0% took 10 or more medications, and none were able to complete the MSAS themselves. Parents reported a median (IQR) of 7 (4-10) concurrent active symptoms. The median (IQR) GSS was 12.1 (5.4-20.8) (range, 0.0-41.2) and the GSS was 9.8 points (95% CI, 5.5-14.1 points) higher for those with worse recent health than usual. Irritability (65.0%), insomnia (55.0%), and pain (54.0%) were the most prevalent symptoms. Each 10-point GSS increase was associated with 12% (95% CI, 4%-19%) higher medication counts, adjusted for age and complex chronic condition count. Among the 54.0% of children with reported pain, 61.0% were prescribed an analgesic. Conclusions and Relevance: These findings suggest that children with SNI reportedly experience substantial symptom burdens and that higher symptom scores are associated with increased medication use. Paired symptom-medication data may help clinicians identify targets for personalized symptom management, including underrecognized or undertreated symptoms.
Asunto(s)
Analgésicos/uso terapéutico , Administración del Tratamiento Farmacológico , Enfermedades del Sistema Nervioso , Padres , Uso Excesivo de Medicamentos Recetados , Evaluación de Síntomas , Síntomas Conductuales/tratamiento farmacológico , Síntomas Conductuales/etiología , Niño , Enfermedad Crónica/tratamiento farmacológico , Enfermedad Crónica/epidemiología , Colorado/epidemiología , Estudios Transversales , Recolección de Datos/estadística & datos numéricos , Femenino , Humanos , Masculino , Administración del Tratamiento Farmacológico/organización & administración , Administración del Tratamiento Farmacológico/normas , Enfermedades del Sistema Nervioso/complicaciones , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Enfermedades del Sistema Nervioso/epidemiología , Dolor/tratamiento farmacológico , Dolor/etiología , Uso Excesivo de Medicamentos Recetados/prevención & control , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Mejoramiento de la Calidad , Índice de Severidad de la Enfermedad , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Trastornos del Inicio y del Mantenimiento del Sueño/etiología , Evaluación de Síntomas/métodos , Evaluación de Síntomas/estadística & datos numéricosRESUMEN
BACKGROUND: Since the declaration COVID-19 as a pandemic, healthcare systems around the world have faced a huge challenge in managing patients with chronic diseases. Patients with migraine were specifically vulnerable to inadequate medical care. We aimed to investigate the "real-world" impact of COVID-19 pandemic on migraine patients, and to identify risk factors for poor outcome. METHODS: We administered an online, self-reported survey that included demographic, migraine-related, COVID-19-specific and overall psychosocial variables between July 15 and July 30, 2020. We recruited a sample of patients with migraine from headache clinic registry and via social media to complete an anonymous survey. Outcomes included demographic variables, change in migraine frequency and severity during the lockdown period, communication with treating physician, compliance to migraine treatment, difficulty in getting medications, medication overuse, symptoms of anxiety and/or depression, sleep and eating habits disturbance, screen time exposure, work during pandemic, use of traditional medicine, effect of Botox injection cancellation, and overall worries and concerns during pandemic. RESULTS: A total of 1018 patients completed the survey. Of the respondents, 859 (84.3%) were females; 733 (71.9%) were aged 20 to 40 years, 630 (61.8%) were married, and 466 (45.7%) reported working during the pandemic. In comparison to pre-pandemic period, 607 respondents (59.6%) reported increase in migraine frequency, 163 (16%) reported decrease in frequency, and 105 (10.3%) transformed to chronic migraine. Severity was reported to increase by 653 (64.1%) respondents. The majority of respondents; 626 (61.5%) did not communicate with their neurologists, 477 (46.9%) reported compliance to treatment, and 597 (58.7%) reported overuse of analgesics. Botox injections cancellation had a negative impact on 150 respondents (66.1%) from those receiving it. Forty-one respondents (4%) were infected with COVID-19; 26 (63.4%) reported worsening of their headaches amid infection period. Sleep disturbance was reported by 794 (78.1%) of respondents, and 809 (79.5%) reported having symptoms of anxiety and/or depression. CONCLUSIONS AND RELEVANCE: COVID-19 pandemic had an overall negative impact on patients with migraine. Several risk factors for poor outcome were identified. Long-term strategies should be validated and implemented to deliver quality care for patients with migraine, with emphasis on psychosocial well-being.
Asunto(s)
Infecciones por Coronavirus/epidemiología , Trastornos Migrañosos/fisiopatología , Neumonía Viral/epidemiología , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricos , Adulto , Analgésicos/uso terapéutico , Ansiedad/psicología , Betacoronavirus , Toxinas Botulínicas Tipo A/uso terapéutico , COVID-19 , Comunicación , Depresión/psicología , Femenino , Accesibilidad a los Servicios de Salud , Humanos , Internet , Kuwait/epidemiología , Masculino , Persona de Mediana Edad , Trastornos Migrañosos/tratamiento farmacológico , Trastornos Migrañosos/prevención & control , Trastornos Migrañosos/psicología , Fármacos Neuromusculares/uso terapéutico , Pandemias , Relaciones Médico-Paciente , Factores de Riesgo , SARS-CoV-2 , Sueño , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Trastornos del Inicio y del Mantenimiento del Sueño/psicología , Encuestas y Cuestionarios , Adulto JovenAsunto(s)
Analgésicos Opioides/uso terapéutico , Artroplastia de Reemplazo de Rodilla/estadística & datos numéricos , Prescripción Inadecuada/prevención & control , Trastornos Relacionados con Opioides/prevención & control , Dolor Postoperatorio/tratamiento farmacológico , Anciano , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osteoartritis de la Rodilla/cirugía , Manejo del Dolor , Uso Excesivo de Medicamentos Recetados/estadística & datos numéricosRESUMEN
INTRODUCTION: Urinary tract infections (UTI) are a common indication for antibiotic use in the emergency department (ED). With antibiotic resistance on the rise, it is essential that antibiotics be prescribed appropriately for UTIs. Our objective was to evaluate the appropriateness of antibiotic prescriptions by ED providers for uncomplicated cystitis and pyelonephritis. METHODS: We conducted a retrospective study of females ages 2-50 years seen in an academic ED from January 2017 to April 2018 diagnosed with UTI. We assessed the appropriateness of discharge antibiotic prescriptions, as determined by adherence to clinical practice guidelines, best evidence for the particular indication (cystitis vs pyelonephritis for children and adults), and the local antibiogram. RESULTS: A total of 421 patients were included in this study. Of these, 60 children and 198 adults were diagnosed with cystitis, and 47 children and 116 adults were diagnosed with pyelonephritis. Treatment in the absence of true infection was common, with culture-confirmed UTI occurring in only 17/50 (34%) of children and 60/129 (47%) of adults diagnosed with cystitis, and 23/40 (58%) of children and 58/87 (67%) of adults diagnosed with pyelonephritis, among patients who had urine cultures. The type of antibiotic prescribed was appropriate in 53/60 (88%) of children and 135/198 (68%) of adults with cystitis, and 38/47 (81%) of children and 53/116 (46%) of adults with pyelonephritis. The most common inappropriate antibiotic types were beta-lactams in adults (n = 92), nitrofurantoin for pyelonephritis (n = 16), and amoxicillin (n = 15). Dosing and duration errors were also common, occurring in 122/279 (44%) of prescriptions of an appropriate antibiotic type. The frequency of errors in the type of antibiotic prescribed was similar among provider types (attending physician, resident physician, and advanced practice clinician; p = 0.926). CONCLUSION: This study reveals room for improvement in antibiotic prescription practices across provider cohorts in the ED for the management of uncomplicated cystitis and pyelonephritis in females.